<DOC>
	<DOCNO>NCT02635061</DOCNO>
	<brief_summary>Determine safety , tolerability , dose limit toxicity ( DLTs ) , maximum tolerate dose ( MTD ) ACY 241 combination nivolumab .</brief_summary>
	<brief_title>Selective HDAC6 Inhibitor ACY 241 Combination With Nivolumab Patients With Unresectable Non Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Must able understand voluntarily sign informed consent form ( ICF ) . 2 . Must ≥ 18 year age time sign ICF . 3 . Must able adhere study visit schedule protocol requirement . 4 . Patients must histologically confirm unresectable NSCLC nivolumab clinically appropriate . Patients must one line prior therapy progress discontinue due toxicity . 5 . Measurable disease Response Evaluation Criteria Solid Tumors version 1.1 ( RECIST 1.1 ) Immune relate Response Criteria ( irRC ) . 6 . Life expectancy &gt; 12 week . 7 . Must Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 , 1 , 2 . 8 . Willingness pre treatment treatment tumor biopsy . 9 . Patients potential pregnancy impregnate partner must agree follow acceptable birth control method avoid conception . Female patient childbearing potential must agree use adequate contraceptive measure 3 month last study drug take . Females childbearing potential must negative pregnancy test . It known antideacetylase activity experimental drug may harmful develop fetus nursing infant . 10 . Male patient willing use barrier contraceptive ( ie , condom ) 3 month last study drug take . 1 . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent patient give informed consent . 2 . Any serious concurrent medical condition , laboratory abnormality , psychiatric illness might make patient nonevaluable , put patient 's safety risk , prevent patient follow study requirement . 3 . Pregnant lactating female . 4 . Patients uncontrolled brain metastasis . Existing brain metastasis must previously treat currently stable . 5 . Patients chemotherapy within 14 day enter study recover AEs ≤ Grade 1 due agent administer 14 day earlier . 6 . Previous therapy histone deacetylase ( HDAC ) inhibitor and/or anti PD 1 , anti PD L1 , anti CTLA4 immunotherapy . 7 . Any following laboratory abnormality : ANC &lt; 1,500/µL Platelet count &lt; 100,000/µL Hematologic growth factor allow Screening first cycle treatment Hemoglobin &lt; 9 g/dL ( &lt; 5.5 mmol/L ; previous red blood cell transfusion permit ) Creatinine &gt; 1.5 × upper limit normal ( ULN ) AST ALT &gt; 2.5 × ULN . For patient liver metastasis AST ALT &gt; 5 × ULN Serum total bilirubin &gt; 1.5 mg/dL &gt; 3 × ULN patient hereditary benign hyperbilirubinemia 8 . Corrected QT interval ( QTc ) use Fridericia 's formula ( QTcF ) value &gt; 480 msec Screening ; family personal history long QTc syndrome ventricular arrhythmia include ventricular bigeminy Screening ; previous history drug induce QTc prolongation need treatment medication know suspected produce prolonged QTc interval electrocardiogram ( ECG ) . 9 . Congestive heart failure ( New York Heart Association Class III IV ) , myocardial infarction within 12 month start study treatment , unstable poorly control angina pectoris , include Prinzmetal variant angina pectoris . 10 . Patients chronic autoimmune disease ( ) require systemic immunosuppression . 11 . Positive human immunodeficiency virus , hepatitis B virus , hepatitis C virus infection . 12 . Patients receive follow within 14 day initiate study treatment : major surgery , radiation therapy , and/or systemic therapy ( standard investigational biological anticancer agent ) . 13 . Current enrollment another clinical study involve treatment and/or receive investigational agent reason , use investigational agent within 14 day initiate study treatment . 14 . Incidence gastrointestinal disease may significantly alter absorption ACY 241 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>